a trial of lopinavirritonavir in adults hospitalized with severe covid-19
a trial of lopinavirritonavir in adults hospitalized with severe covid-19
the question of whether earlier lopinavirritonavir treatment in covid-19 could have clinical benefit is an important one that requires further study.", "a recent report showed that the median duration of viral shedding in covid-19 was 20 days in patients with severe illness and could be as long as 37 days.24 neither that study nor the current one found evidence that lopinavirritonavir exerted a significant antiviral effect.")